Filters

Tackling

Global health challenges

Tuberculosis

Tuberculosis

IFPMA member companies are working on increasing R&D for improved treatments and new vaccines for TB and MDR-TB, as well as partnering with others to expand access to treatment, diagnostics and care for patients.

IFPMA endorses WHO’s End TB Strategy, envisioning a world free of TB with zero deaths, disease and suffering. Our industry is involved in a wide-ranging number of initiatives to support the global health community in achieving this vision.

Tuberculosis (TB) is one of the world’s deadliest communicable diseases. In 2013, an estimated 9 million people developed TB and 1.5 million died from the disease, 360,000 of whom were HIV-positive. Worldwide, the proportion of new cases with multi-drug resistant TB (MDR-TB) was 3.5% in 2013 and has not changed compared with recent years. TB is curable, but its long treatment regimen is demanding and unfortunately is difficult for patients to successfully complete.

IFPMA member companies are working to develop improved treatments for TB and MDR-TB, as well as to develop new vaccines to stem the spread of this disease. Engagement unfolds around three main areas: research and development, access, capacity building, and advocacy. A key driver underpinning these areas is partnerships.

Between 2012 and 2014, 3 new treatments were approved for MDR-TB and latent TB infection, and there are currently an additional 50 R&D projects for medicines and vaccines in the pipeline, including 10 promising products in the late stages of development and three in phase III clinical trials. Companies are partnering with national governments, research institutes, product development partnerships and NGOs in 15 programs to develop innovative medicines and vaccines. These include WIPO Re:Search a consortium providing access to intellectual property, pharmaceutical compounds, technologies, know-how and data for several diseases including TB; the Global Health Innovative Technology Fund (GHIT), as well as Aeras or the Gates TB Drug Accelerator (TBDA).

Our companies are involved in 15 partnerships to increase access to TB treatment, diagnosis and care. These programs include technology transfers with generics companies in countries with a high-burden of MDR-TB to increase local capacity in the manufacturing of MDR-TB medicines, reaching isolated groups with TB diagnostics through door-to-door screenings, training of health workers, preventing medicine stock-outs in rural health centres by working with mHealth providers.

Many member companies are involved in projects to support the WHO and global advocacy groups to accelerate social and political action to stop the spread of TB.

tuberculosis_2

Our member companies are also very active in the global fight against fake medicines. It is estimated that 700’000 people die because of fake TB and malaria medicines every year. Fake TB medicines contribute to the spread of MDR TB and undermine efforts to reverse the global TB epidemic.

9.6 million people

fell ill with TB in 2014

95% of TB deaths

occur in LMDCs

480 000 people

developed (MDR-TB) in the world in 2014

Related Resources


Links


Subtopics


Tags